PHIO PHARMACEUTICALS CORP (PHIO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.85-5.64%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · PHIO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
PHIO — earnings in line
Dated 2026-08-06
and attached as Exhibit 99.1 to this Report will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.
Why it matters: FDA feedback can show whether the planned skin cancer study design can move ahead.
Watch forThe company reports FDA feedback that supports the proposed Phase 2b study design and next steps.
Also watch forThe FDA asks for major new studies or a different trial design before Phase 2b can start.
Why it matters: Starting on time would show the company cleared key trial, supply, and FDA steps.
Supportive ifThe company announces that it has begun enrolling or dosing patients in the PH-762 Phase 2b study by March 31, 2027.
Worry ifThe company reports that the Phase 2b study has not started by March 31, 2027, or pushes the start date later.
Why it matters: The update can show whether the FDA, supply, and trial dates remain on track.
Watch forThe November 12 update confirms the Q1 2027 Phase 2b start plan and reports no new delay in FDA or supply work.
Also watch forThe November 12 update gives a later Phase 2b start date or reports a new FDA or supply delay.
Why it matters: The company reported $13.0 million in cash and said it could fund planned work into the second half of 2027.
Worry ifA later report shows cash below $13.0 million. Management says funds no longer cover planned work into the second half of 2027.
Less concerning ifCash remains at or above $13.0 million, or management still says funds cover planned work into the second half of 2027.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$196 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $660 loss on $10,000 · 6.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,847 loss on $10,000 · 48.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.